Intravenous Iron Drugs Market Size, Share, Demand & Trends Analysis Report by 2025

Intravenous Iron Drugs Market Insights

The global Intravenous Iron Drugs Market size was valued at USD 2.88 Billion in 2023 and is predicted to reach USD 6.00 Billion by the end of 2032. The market is expected to grow with a CAGR of 8.5% during the forecast period. The report analyzes the global Intravenous Iron Drugs Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Intravenous Iron Drugs industry.

Request Free Sample

Intravenous Iron Drugs Market: Industry Perspective

Iron is one of the several minerals present inside the human body. Iron is a component of hemoglobin, which makes it an important mineral. The deficiency of iron in the body leads to an inability in making hemoglobin, which may result in the occurrence of anemia. The anemia arising due to low iron levels is identified as iron-deficiency anemia. Women and elderly people are at a greater risk of developing iron-deficiency anemia. Oral iron supplementation is provided to treat iron-deficiency. However, some people cannot take oral iron supplementation. People who are affected with inflammatory bowel disease, patients undergoing kidney dialysis, iron-deficiency anemia patients undergoing heavy blood loss surgery, and celiac disease patients among others are given intravenous iron drugs.

The report covers forecasts and analyses for the intravenous iron drugs market on a global and regional level. The study provides historic data from 2018 along with a forecast from 2024 to 2032 based on revenue (USD Million). The study includes drivers and restraints for the intravenous iron drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the intravenous iron drugs market on a global as well as regional level.

Request Free Sample

In order to give the users of this report a comprehensive view of the intravenous iron drugs market, we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein the product and services segment is benchmarked based on their market size, growth rate, and general attractiveness.

The report provides a company market share analysis in order to give a broader overview of the key players in the intravenous iron drugs market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the intravenous iron drugs market on a global and regional basis.

Intravenous Iron Drugs Market Growth Factors

Factors such as increasing incidence of chronic renal disease, increasing geriatric population, a growing number of dialysis patients, increasing cases of iron-deficiency anemia, an increasing number of surgeries, and growing investment in research and development by major manufacturers will act as major driving factors in the growth of global intravenous iron drugs market.

Development of novel products, the growing need for prevention of anemia in pregnant women, and growing use in gynecology will act as an opportunity for the market players in the intravenous iron drugs market. Nonetheless, some side-effects associated with intravenous iron drugs, stringent regulations, high cost as compared to oral supplements, and complex approval process will restrict the growth of the global intravenous iron drugs market.

Intravenous Iron Drugs Market Segmentation Analysis

The global intravenous iron drugs market has been split into product, application, and region. Based on product, the intravenous iron drugs market has been segmented into ferric carboxymaltose, iron sucrose, iron dextran, and others. The ferric carboxymaltose segment accounted for the highest market share in 2018 due to growing applications of ferric carboxymaltose in drug discovery and reduction in costs.

The application segment has been segmented into cancer, inflammatory bowel disease, chronic kidney disease, and other diseases. The chronic kidney disease segment accounted for the highest market share in 2018 due to its growing prevalence, increasing geriatric population, and growing inclination towards a sedentary lifestyle.

Intravenous Iron Drugs Market: Report Scope

North America will be the leading region during the forecast period. High investment in research and development of intravenous iron drugs, applications in the field of cancer research, and growing adoption of intravenous iron drugs will boost the market growth in this region. Europe will be the second largest market. The major reasons are the advantageous reimbursement scenario, high diabetes prevalence, and the presence of key market players.

The Asia Pacific will propagate at a speedy rate over the forecast period due to the launch of novel products, the high prevalence of chronic renal ailments, and growing investment by the government in the biopharmaceutical industry. The Latin American market will develop at a significant rate during the forecast period. The Africa and Middle Eastern region is likely to exhibit perceptible progression in the projected time-frame.

Some of the leading players in the global market include

• Daiichi Sankyo Company Ltd.
• Allergan Inc.
• Sanofi
• Rockwell Medical Technologies Inc.
• Fresenius Medical Care AG & Co.
• AMAG Pharmaceuticals. Inc.
• Pharmacosmos A/S
• Vifor Pharma Management Ltd.
• American Regent. Inc.
• Shield Therapeutics Plc

This report segments the Global Intravenous Iron Drugs Market as follows:

By Product Analysis

• Ferric carboxymaltose
• Iron Sucrose
• Iron Dextran
• Others

By Application Analysis

• Cancer
• Inflammatory Bowel Disease
• Chronic Kidney Disease
• Other Diseases

By Region Analysis

• North America

  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of The Middle East & Africa